

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東新華製藥股份有限公司

Shandong Xinhua Pharmaceutical Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 00719)

**THE TERMINATION OF THE EQUITY
ACQUISITION INTENTION AGREEMENT**

This is a voluntary announcement made by Shandong Xinhua Pharmaceutical Company Limited (i.e. the Company).

Reference is made to the announcement of the Company dated 9 December 2024 (the “Announcement”) regarding the formal signing of the equity acquisition intention agreement between the Company and NovoSana (Europe) B.V.. Unless the context herein defines otherwise, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement.

The equity acquisition intention agreement is only a preliminary intention reached by the parties through friendly negotiations. However, after further discussions and negotiations, the parties were not able to reach a consensus on the terms and conditions of the formal agreement. As a result, the Company did not proceed with entering into a formal agreement for the Project, and the Project will not proceed. Accordingly, the Company has decided to terminate the equity acquisition intention agreement.

The termination of the equity acquisition intention agreement is a decision made by the Company after prudent consideration. The termination will not affect the Company’s current production and operating activities, will not have any adverse impact on the Company’s development and does not involve any circumstances that would prejudice the interests of the Company and all shareholders, especially its minority shareholders.

Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the shares of the Company.

By Order of the Board
**Shandong Xinhua Pharmaceutical Company
Limited**
He Tongqing
Chairman

6 February 2026, Zibo, the PRC

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. He Tongqing (Chairman)
Mr. Xu Wenhui
Mr. Hou Ning

Non-executive Directors:

Mr. Xu Lie
Mr. Zhang Chengyong

Independent Non-executive Directors:

Mr. Pan Guangcheng
Mr. Zhu Jianwei
Mr. Ling Peixue
Ms. Cheung Ching Ching, Daisy